Advertisement

neurogenetics

, Volume 14, Issue 2, pp 99–111 | Cite as

MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways

  • Alex R. PaciorkowskiEmail author
  • Ryan N. Traylor
  • Jill A. Rosenfeld
  • Jacqueline M. Hoover
  • Catharine J. Harris
  • Susan Winter
  • Yves Lacassie
  • Martin Bialer
  • Allen N. Lamb
  • Roger A. Schultz
  • Elizabeth Berry-Kravis
  • Brenda E. Porter
  • Marni Falk
  • Anu Venkat
  • Rena J. Vanzo
  • Julie S. Cohen
  • Ali Fatemi
  • William B. Dobyns
  • Lisa G. Shaffer
  • Blake C. Ballif
  • Eric D. Marsh
Original Article

Abstract

MEF2C haploinsufficiency syndrome is an emerging neurodevelopmental disorder associated with intellectual disability, autistic features, epilepsy, and abnormal movements. We report 16 new patients with MEF2C haploinsufficiency, including the oldest reported patient with MEF2C deletion at 5q14.3. We detail the neurobehavioral phenotype, epilepsy, and abnormal movements, and compare our subjects with those previously reported in the literature. We also investigate Mef2c expression in the developing mouse forebrain. A spectrum of neurofunctional deficits emerges, with hyperkinesis a consistent finding. Epilepsy varied from absent to severe, and included intractable myoclonic seizures and infantile spasms. Subjects with partial MEF2C deletion were statistically less likely to have epilepsy. Finally, we confirm that Mef2c is present both in dorsal primary neuroblasts and ventral gamma-aminobutyric acid(GABA)ergic interneurons in the forebrain of the developing mouse. Given interactions with several key neurodevelopmental genes such as ARX, FMR1, MECP2, and TBR1, it appears that MEF2C plays a role in several developmental stages of both dorsal and ventral neuronal cell types.

Keywords

MEF2C haploinsufficiency Intellectual disability Autism Infant-onset myoclonic epilepsy Infantile spasms Hyperkinesis Deletion 5q14.3 

Notes

Acknowledgments

We wish to thank the families of the subjects for sharing the details of their children’s condition with us. We recognize Natasha Vedage and Molly Bourke for their assistance with the immunohistochemistry, Erin Dodge for assistance with figure design, and Hailly Butler for assistance with subject consents.

Disclosures

WBD is funded by NINDS R01 NS058721; JAR and RAS are employees of Signature Genomic Laboratories, PerkinElmer; ANL is an employee of ARUP Laboratories; and RJV is an employee of Lineagen, Inc. The other authors have no disclosures.

Supplementary material

10048_2013_356_MOESM1_ESM.doc (96 kb)
ESM 1 (DOC 96 kb)
10048_2013_356_MOESM2_ESM.mpg (7.5 mb)
Video 1 Subject LR11-325 at 5 months, showing paroxysms of hyperkinetic movements of the arms and legs. These were not associated with epileptiform discharges on EEG. (MPG 7636 kb)
Video 2

Subject IS09-024 at 12 years, showing stereotypic hyperkinetic movements of the distal upper extremities. (AVI 6156 kb)

References

  1. 1.
    Berland S, Houge G (2010) Late-onset gain of skills and peculiar jugular pit in an 11-year-old girl with 5q14.3 microdeletion including MEF2C. Clin Dysmorphol 19(4):222–224PubMedCrossRefGoogle Scholar
  2. 2.
    Carr CW, Zimmerman HH, Martin CL, Vikkula M, Byrd AC, Abdul-Rahman OA (2011) 5q14.3 neurocutaneous syndrome: a novel continguous gene syndrome caused by simultaneous deletion of RASA1 and MEF2C. Am. J. Med. Genet. A 155A(7):1640–1645PubMedGoogle Scholar
  3. 3.
    Engels H, Wohlleber E, Zink A, Hoyer J, Ludwig KU, Brockschmidt FF et al (2009) A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients. Eur J Hum Genet 17(12):1592–1599PubMedCrossRefGoogle Scholar
  4. 4.
    Le Meur N, Holder-Espinasse M, Jaillard S, Goldenberg A, Joriot S, Amati-Bonneau P et al (2010) MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. J Med Genet 47(1):22–29PubMedCrossRefGoogle Scholar
  5. 5.
    Novara F, Beri S, Giorda R, Ortibus E, Nageshappa S, Darra F et al (2010) Refining the phenotype associated with MEF2C haploinsufficiency. Clin Genet 78(5):471–477PubMedCrossRefGoogle Scholar
  6. 6.
    Nowakowska BA, Obersztyn E, Szymańska K, Bekiesińska-Figatowska M, Xia Z, Ricks CB et al (2010) Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C. Am J Med Genet B Neuropsychiatr Genet 153B(5):1042–1051PubMedGoogle Scholar
  7. 7.
    Zweier M, Gregor A, Zweier C, Engels H, Sticht H, Wohlleber E et al (2010) Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression. Hum Mutat 31(6):722–733PubMedCrossRefGoogle Scholar
  8. 8.
    Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, Rutledge SL et al (2011) Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. Am J Med Genet A 155A(10):2386–2396PubMedGoogle Scholar
  9. 9.
    Zweier M, Rauch A (2012) The MEF2C-related and 5q14.3q15 microdeletion syndrome. Mol Syndromol 2(3–5):164–70PubMedGoogle Scholar
  10. 10.
    Li Z, McKercher SR, Cui J, Nie Z, Soussou W, Roberts AJ et al (2008) Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells. J Neurosci 28(26):6557–6568PubMedCrossRefGoogle Scholar
  11. 11.
    Potthoff MJ, Olson EN (2007) MEF2: a central regulator of diverse developmental programs. Development 134(23):4131–4140PubMedCrossRefGoogle Scholar
  12. 12.
    Leifer D, Krainc D, Yu YT, McDermott J, Breitbart RE, Heng J et al (1993) MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc Natl Acad Sci U S A 90(4):1546–1550PubMedCrossRefGoogle Scholar
  13. 13.
    Lyons GE, Micales BK, Schwarz J, Martin JF, Olson EN (1995) Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J Neurosci 15(8):5727–5738PubMedGoogle Scholar
  14. 14.
    Janson CG, Chen Y, Li Y, Leifer D (2001) Functional regulatory regions of human transcription factor MEF2C. Brain Res Mol Brain Res 97(1):70–82PubMedCrossRefGoogle Scholar
  15. 15.
    Sekiyama Y, Suzuki H, Tsukahara T (2012) Functional gene expression analysis of tissue-specific isoforms of Mef2c. Cell Mol Neurobiol 32(1):129–139PubMedCrossRefGoogle Scholar
  16. 16.
    Li H, Radford JC, Ragusa MJ, Shea KL, McKercher SR, Zaremba JD et al (2008) Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc Natl Acad Sci U S A 105(27):9397–9402PubMedCrossRefGoogle Scholar
  17. 17.
    Barbosa AC, Kim M-S, Ertunc M, Adachi M, Nelson ED, McAnally J et al (2008) MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc Natl Acad Sci U S A 105(27):9391–9396PubMedCrossRefGoogle Scholar
  18. 18.
    Bedogni F, Hodge RD, Elsen GE, Nelson BR, Daza RAM, Beyer RP et al (2010) Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. Proc Natl Acad Sci U S A 107(29):13129–13134PubMedCrossRefGoogle Scholar
  19. 19.
    Fulp CT, Cho G, Marsh ED, Nasrallah IM, Labosky PA, Golden JA (2008) Identification of Arx transcriptional targets in the developing basal forebrain. Hum Mol Genet 17(23):3740–3760PubMedCrossRefGoogle Scholar
  20. 20.
    Long JE, Cobos I, Potter GB, Rubenstein JLR (2009) Dlx1&2 and Mash1 transcription factors control MGE and CGE patterning and differentiation through parallel and overlapping pathways. Cereb Cortex 19(Suppl 1):i96–i106PubMedCrossRefGoogle Scholar
  21. 21.
    Battini R, Sgandurra G, Petacchi E, Guzzetta A, Di Pietro R, Giannini MT et al (2008) Movement disorder-childhood rating scale: reliability and validity. Pediatr Neurol 39(4):259–265PubMedCrossRefGoogle Scholar
  22. 22.
    Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW et al (2010) Definition and classification of hyperkinetic movements in childhood. Mov Disord 25(11):1538–1549PubMedCrossRefGoogle Scholar
  23. 23.
    Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH, Bejjani BA et al (2008) Identification of a previously unrecognized microdeletion syndrome of 16q11.2q12.2. Clin Genet 74(5):469–475PubMedCrossRefGoogle Scholar
  24. 24.
    Marsh ED, Minarcik J, Campbell K, Brooks-Kayal AR, Golden JA (2008) FACS-array gene expression analysis during early development of mouse telencephalic interneurons. Dev Neurobiol 68(4):434–445PubMedCrossRefGoogle Scholar
  25. 25.
    Batista-Brito R, Machold R, Klein C, Fishell G (2008) Gene expression in cortical interneuron precursors is prescient of their mature function. Cereb Cortex 18(10):2306–2317PubMedCrossRefGoogle Scholar
  26. 26.
    Winden KD, Oldham MC, Mirnics K, Ebert PJ, Swan CH, Levitt P et al (2009) The organization of the transcriptional network in specific neuronal classes. Mol Syst Biol 5:291PubMedCrossRefGoogle Scholar
  27. 27.
    Chahrour M, Jung SY, Shaw C, Zhou X, Wong STC, Qin J et al (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320(5880):1224–1229PubMedCrossRefGoogle Scholar
  28. 28.
    Cardoso C, Boys A, Parrini E, Mignon-Ravix C, McMahon JM, Khantane S et al (2009) Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology 72(9):784–792PubMedCrossRefGoogle Scholar
  29. 29.
    Saitsu H, Igarashi N, Kato M, Okada I, Kosho T, Shimokawa O et al (2011) De novo 5q14.3 translocation 121.5-kb upstream of MEF2C in a patient with severe intellectual disability and early-onset epileptic encephalopathy. Am J Med Genet A 155(11):2879–84CrossRefGoogle Scholar
  30. 30.
    Toral-López J, Buentello-Volante B, Balderas-Minor MM, Amezcua-Herrera C, Valdes-Miranda JM, González-Huerta LM et al (2012) An intellectually disabled patient with the 5q14.3q15 microdeletion syndrome associated with an apparently de novo t(2;5)(q13;q14). Am J Med Genet A 158A(4):942–946PubMedCrossRefGoogle Scholar
  31. 31.
    Strømme P, Mangelsdorf ME, Scheffer IE, Gécz J (2002) Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Brain Dev 24(5):266–268PubMedCrossRefGoogle Scholar
  32. 32.
    Guerrini R, Moro F, Kato M, Barkovich AJ, Shiihara T, McShane MA et al (2007) Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology 69(5):427–433PubMedCrossRefGoogle Scholar
  33. 33.
    Brunetti-Pierri N, Paciorkowski AR, Ciccone R, Mina ED, Bonaglia MC, Borgatti R et al (2011) Duplications of FOXG1 in 14q12 are associated with developmental epilepsy, mental retardation, and severe speech impairment. Eur J Hum Genet 19(1):102–107PubMedCrossRefGoogle Scholar
  34. 34.
    Kortüm F, Das S, Flindt M, Morris-Rosendahl DJ, Stefanova I, Goldstein A et al (2011) The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet 48(6):396–406PubMedCrossRefGoogle Scholar
  35. 35.
    Percy AK (2002) Rett syndrome. Current status and new vistas. Neurol Clin 20(4):1125–1141PubMedCrossRefGoogle Scholar
  36. 36.
    Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N et al (2010) Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68(6):944–950PubMedCrossRefGoogle Scholar
  37. 37.
    Pfeiffer BE, Zang T, Wilkerson JR, Taniguchi M, Maksimova MA, Smith LN et al (2010) Fragile X mental retardation protein is required for synapse elimination by the activity-dependent transcription factor MEF2. Neuron 66(2):191–197PubMedCrossRefGoogle Scholar
  38. 38.
    Tonk V, Kyhm JH, Gibson CE, Wilson GN (2011) Interstitial deletion 5q14.3q21.3 with MEF2C haploinsufficiency and mild phenotype: when more is less. Am J Med Genet A 155A(6):1437–1441PubMedGoogle Scholar
  39. 39.
    Bienvenu T, Diebold B, Chelly J, Isidor B (2012) Refining the phenotype associated with MEF2C point mutations. Neurogenetics. doi: 10.1007/s10048-012-0344-7

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Alex R. Paciorkowski
    • 1
    Email author
  • Ryan N. Traylor
    • 2
  • Jill A. Rosenfeld
    • 2
  • Jacqueline M. Hoover
    • 3
  • Catharine J. Harris
    • 4
  • Susan Winter
    • 5
  • Yves Lacassie
    • 6
  • Martin Bialer
    • 7
  • Allen N. Lamb
    • 8
  • Roger A. Schultz
    • 2
  • Elizabeth Berry-Kravis
    • 9
  • Brenda E. Porter
    • 10
  • Marni Falk
    • 11
  • Anu Venkat
    • 12
  • Rena J. Vanzo
    • 13
  • Julie S. Cohen
    • 14
  • Ali Fatemi
    • 14
  • William B. Dobyns
    • 15
  • Lisa G. Shaffer
    • 2
    • 16
  • Blake C. Ballif
    • 2
    • 16
  • Eric D. Marsh
    • 12
  1. 1.Departments of Neurology, Pediatrics, and Biomedical Genetics, Center for Neural Development & DiseaseUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Signature Genomic Laboratories, PerkinElmer, Inc.SpokaneUSA
  3. 3.Department of Medical GeneticsChildren’s Hospital of PittsburghPittsburghUSA
  4. 4.Division of Medical Genetics, Department of Child HealthUniversity of MissouriColumbiaUSA
  5. 5.Department of Medical Genetics/MetabolismChildren’s Hospital of Central CaliforniaMaderaUSA
  6. 6.Department of PediatricsLouisiana State University Health Sciences Center, New Orleans, LA and Children’s HospitalNew OrleansUSA
  7. 7.Division of Medical GeneticsNorth Shore Long Island Jewish Health SystemNew Hyde ParkUSA
  8. 8.ARUP LaboratoriesUniversity of UtahSalt Lake CityUSA
  9. 9.Departments of Pediatrics, Neurological Sciences & BiochemistryRush University Medical CenterChicagoUSA
  10. 10.Department of NeurologyStanford UniversityStanfordUSA
  11. 11.Department of Medical GeneticsChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  12. 12.Department of NeurologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  13. 13.Lineagen, Inc.Salt Lake CityUSA
  14. 14.Division of Neurogenetics, Kennedy Krieger InstituteJohns Hopkins Medical InstitutionsBaltibmoreUSA
  15. 15.Division of Genetic Medicine, Department of PediatricsUniversity of Washington and Seattle Children’s Research InstituteSeattleUSA
  16. 16.Paw Print Genetics, Genetic Veterinary Sciences, Inc.SpokaneUSA

Personalised recommendations